Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Unlocking New Potential: Insights from the LAPIS Phase 3 Trial on Pamrevlumab in Locally Advanced Pancreatic Cancer

    Editor’s note: The LAPIS Phase 3 trial was a large-scale, global, double-blind, placebo-controlled study designed to assess the efficacy of pamrevlumab in combination with chemotherapy for patients with locally advanced…

    2025.02.13
  • The 8th Yunling Breast Cancer Summit Forum | Dr. Qianjun Chen: Focusing on Controversies in HER2-Positive Breast Cancer, Multidisciplinary Collaboration Holds Great Promise

    On July 14, to mark the 40th anniversary of Yunnan Cancer Hospital, the “8th Yunling Breast Cancer Summit Forum,” hosted by the Yunnan Anti-Cancer Association and the Chinese Medical Education Association, was held in Kunming. The event gathered cutting-edge advances in breast cancer from domestic and international experts. Dr. Qianjun Chen from Guangdong Provincial Hospital…

    2025.02.13
  • NIAGARA Study: A Potential New Standard for Muscle-Invasive Bladder Cancer?

    The Phase 3 NIAGARA trial, presented at ASCO GU 2025, provides compelling evidence supporting perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC). The study highlights significant…

    2025.02.13
  • Blood Science Update: Gut Microbiota in Benign and Malignant Hematopoiesis

    This article, published in the esteemed journal Blood Science, highlights the intricate role of gut microbiota in hematopoiesis, encompassing its influence on both benign and malignant conditions. As a peer-reviewed platform at the forefront of clinical and experimental hematology, Blood Science is recognized for its impact on advancing our understanding of molecular biology, physiology, and…

    2025.02.13
  • Blood Science Update: Epigenetic Modifications in Hematopoietic Ecosystem: A Key Tuner from Homeostasis to Acute Myeloid Leukemia

    Blood Science, an authoritative journal in the fields of hematology and oncology, has been at the forefront of advancing knowledge in blood-related disorders. Dedicated to publishing pioneering research, the journal provides a platform for understanding the complexities of blood ecosystems, from cellular mechanisms to clinical implications. By fostering collaboration and disseminating groundbreaking studies, Blood Science…

    2025.02.13
  • Blood Science Update: New Insights into the Endothelial Origin of the Hematopoietic System

    This article, published in the journal Blood Science, elucidates groundbreaking advancements in understanding the endothelial origins of the hematopoietic system. As a leading platform in clinical and experimental hematology, Blood Science continues to publish high-impact research that transforms molecular biology and physiology. Authored by Professor Yu Lan from the Key Laboratory for Regenerative Medicine of…

    2025.02.13
  • Major Trial Challenges Role of Auto-HCT in Mantle Cell Lymphoma

    New findings from the ECOG-ACRIN EA4151 Phase 3 trial, published in Blood on November 25, 2024, could change clinical practice for mantle cell lymphoma (MCL).For years, autologous hematopoietic cell transplantation…

    2025.02.13
  • Major Trial Challenges Role of Auto-HCT in Mantle Cell Lymphoma

    New findings from the ECOG-ACRIN EA4151 Phase 3 trial, published in Blood on November 25, 2024, could change clinical practice for mantle cell lymphoma (MCL).For years, autologous hematopoietic cell transplantation…

    2025.02.13
«previous next»
Recent Posts
  • Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?
  • Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy
  • Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations
  • Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance
  • Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top